Efficacy of Semaglutide in Pediatric Patients With Bardet-Biedl Syndrome and Alström Syndrome

<p dir="ltr">Bardet-Biedl syndrome (BBS) and Alström syndrome (AS) are rare autosomal recessive ciliopathies characterized by severe multisystemic involvement, including metabolic, sensory, and developmental impairments. Both conditions result from primary cilia dysfunction, disrupti...

Full description

Saved in:
Bibliographic Details
Main Author: Hajar Dauleh (18002500) (author)
Other Authors: Idris Mohammed (751020) (author), Khalid Hussain (110443) (author)
Published: 2025
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1864513523982270464
author Hajar Dauleh (18002500)
author2 Idris Mohammed (751020)
Khalid Hussain (110443)
author2_role author
author
author_facet Hajar Dauleh (18002500)
Idris Mohammed (751020)
Khalid Hussain (110443)
author_role author
dc.creator.none.fl_str_mv Hajar Dauleh (18002500)
Idris Mohammed (751020)
Khalid Hussain (110443)
dc.date.none.fl_str_mv 2025-12-12T15:00:00Z
dc.identifier.none.fl_str_mv 10.1210/jcemcr/luaf266
dc.relation.none.fl_str_mv https://figshare.com/articles/journal_contribution/Efficacy_of_Semaglutide_in_Pediatric_Patients_With_Bardet-Biedl_Syndrome_and_Alstr_m_Syndrome/31239460
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Biomedical and clinical sciences
Medical biochemistry and metabolomics
Paediatrics
Alström syndrome
Bardet-Biedl syndrome
semaglutide
obesity
GLP-1 agonist
dc.title.none.fl_str_mv Efficacy of Semaglutide in Pediatric Patients With Bardet-Biedl Syndrome and Alström Syndrome
dc.type.none.fl_str_mv Text
Journal contribution
info:eu-repo/semantics/publishedVersion
text
contribution to journal
description <p dir="ltr">Bardet-Biedl syndrome (BBS) and Alström syndrome (AS) are rare autosomal recessive ciliopathies characterized by severe multisystemic involvement, including metabolic, sensory, and developmental impairments. Both conditions result from primary cilia dysfunction, disrupting pathways such as leptin and insulin signaling, which leads to obesity and insulin resistance. While setmelanotide, a melanocortin-4 receptor agonist, may be an effective therapy for obesity in these conditions (especially BBS), its cost limits accessibility for many patients. We describe two pediatric cases (one with BBS and another with AS) demonstrating significant metabolic improvements with semaglutide, a glucagon-like peptide-1 receptor agonist. These observations suggest that some cases of BBS and AS may be treated with semaglutide.</p><h2 dir="ltr">Other Information</h2><p dir="ltr">Published in: JCEM Case Reports<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1210/jcemcr/luaf266" target="_blank">https://dx.doi.org/10.1210/jcemcr/luaf266</a></p>
eu_rights_str_mv openAccess
id Manara2_657b2c6cb98ba935502f5762b3c01a54
identifier_str_mv 10.1210/jcemcr/luaf266
network_acronym_str Manara2
network_name_str Manara2
oai_identifier_str oai:figshare.com:article/31239460
publishDate 2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling Efficacy of Semaglutide in Pediatric Patients With Bardet-Biedl Syndrome and Alström SyndromeHajar Dauleh (18002500)Idris Mohammed (751020)Khalid Hussain (110443)Biomedical and clinical sciencesMedical biochemistry and metabolomicsPaediatricsAlström syndromeBardet-Biedl syndromesemaglutideobesityGLP-1 agonist<p dir="ltr">Bardet-Biedl syndrome (BBS) and Alström syndrome (AS) are rare autosomal recessive ciliopathies characterized by severe multisystemic involvement, including metabolic, sensory, and developmental impairments. Both conditions result from primary cilia dysfunction, disrupting pathways such as leptin and insulin signaling, which leads to obesity and insulin resistance. While setmelanotide, a melanocortin-4 receptor agonist, may be an effective therapy for obesity in these conditions (especially BBS), its cost limits accessibility for many patients. We describe two pediatric cases (one with BBS and another with AS) demonstrating significant metabolic improvements with semaglutide, a glucagon-like peptide-1 receptor agonist. These observations suggest that some cases of BBS and AS may be treated with semaglutide.</p><h2 dir="ltr">Other Information</h2><p dir="ltr">Published in: JCEM Case Reports<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1210/jcemcr/luaf266" target="_blank">https://dx.doi.org/10.1210/jcemcr/luaf266</a></p>2025-12-12T15:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1210/jcemcr/luaf266https://figshare.com/articles/journal_contribution/Efficacy_of_Semaglutide_in_Pediatric_Patients_With_Bardet-Biedl_Syndrome_and_Alstr_m_Syndrome/31239460CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/312394602025-12-12T15:00:00Z
spellingShingle Efficacy of Semaglutide in Pediatric Patients With Bardet-Biedl Syndrome and Alström Syndrome
Hajar Dauleh (18002500)
Biomedical and clinical sciences
Medical biochemistry and metabolomics
Paediatrics
Alström syndrome
Bardet-Biedl syndrome
semaglutide
obesity
GLP-1 agonist
status_str publishedVersion
title Efficacy of Semaglutide in Pediatric Patients With Bardet-Biedl Syndrome and Alström Syndrome
title_full Efficacy of Semaglutide in Pediatric Patients With Bardet-Biedl Syndrome and Alström Syndrome
title_fullStr Efficacy of Semaglutide in Pediatric Patients With Bardet-Biedl Syndrome and Alström Syndrome
title_full_unstemmed Efficacy of Semaglutide in Pediatric Patients With Bardet-Biedl Syndrome and Alström Syndrome
title_short Efficacy of Semaglutide in Pediatric Patients With Bardet-Biedl Syndrome and Alström Syndrome
title_sort Efficacy of Semaglutide in Pediatric Patients With Bardet-Biedl Syndrome and Alström Syndrome
topic Biomedical and clinical sciences
Medical biochemistry and metabolomics
Paediatrics
Alström syndrome
Bardet-Biedl syndrome
semaglutide
obesity
GLP-1 agonist